Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 04, 2023

BUY
$3.17 - $5.82 $2.33 Million - $4.28 Million
735,559 New
735,559 $2.5 Million
Q1 2021

May 17, 2021

SELL
$20.81 - $45.5 $414,139 - $905,495
-19,901 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$23.94 - $46.81 $476,429 - $931,565
19,901 New
19,901 $799,000

Others Institutions Holding ALVR

About Allovir, Inc.


  • Ticker ALVR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,063,400
  • Market Cap $933M
  • Description
  • Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...
More about ALVR
Track This Portfolio

Track Maven Securities LTD Portfolio

Follow Maven Securities LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Maven Securities LTD, based on Form 13F filings with the SEC.

News

Stay updated on Maven Securities LTD with notifications on news.